Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol

Journal of Proteomics

Volumn 73, Issue 5, 2010, Pages 1018-1027

  Fischer, Juliana de Saldanha da Gama ^a,b   Liao, Lujian ^b   Carvalho, Paulo C ^b,c   Barbosa, Valmir C ^c   Domont, Gilberto B ^a   Carvalho, Maria da Gloria da Costa ^c   Yates III, John R ^b  

^a Institute of Chemistry   (Brazil)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

A172 cells; ERK; Glioblastoma; GSK3 ; MudPIT; Perillyl alcohol; Time course

Indexed keywords

CAVEOLIN; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PERILLYL ALCOHOL; RAS PROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FUNCTIONAL PROTEOMICS; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CLUSTER ANALYSIS; GLIOBLASTOMA; HUMANS; MONOTERPENES; PHOSPHORYLATION; PROTEOMICS;

EID: 77249176062     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.01.003     Document Type: Article

References (63)

1. da Fonseca C.O., Landeiro J.A., Clark S.S., Quirico-Santos T., da Costa Carvalho M.G., and Gattass C.R. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol 65 Suppl 1 (2006) S1
2. Clark S.S., Zhong L., Filiault D., Perman S., Ren Z., Gould M., et al. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion. Clin Cancer Res 12 (2003) 4494-4504
3. Yeruva L., Pierre K.J., Elegbede A., Wang R.C., and Carper S.W. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 2 (2007) 216-226
4. Clark S.S. Perillyl alcohol induces c-Myc-dependent apoptosis in Bcr/Abl-transformed leukemia cells. Oncology 1 (2006) 13-18
5. Chung B.H., Lee H.Y., Lee J.S., and Young C.Y. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 2 (2006) 222-228
6. Yuri T., Danbara N., Tsujita-Kyutoku M., Kiyozuka Y., Senzaki H., Shikata N., et al. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 3 (2004) 251-260
7. Loutrari H., Hatziapostolou M., Skouridou V., Papadimitriou E., Roussos C., Kolisis F.N., et al. Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 2 (2004) 568-575
8. Teruszkin B.I., ves de P.S., Henriques S.N., Curie C.M., Gibaldi D., Bozza M., et al. Effects of perillyl alcohol in glial C6 cell line in vitro and anti-metastatic activity in chorioallantoic membrane model. Int J Mol Med 6 (2002) 785-788
9. Meadows S.M., Mulkerin D., Berlin J., Bailey H., Kolesar J., Warren D., et al. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 2-3 (2002) 125-128
10. Stearns V., Coop A., Singh B., Gallagher A., Yamauchi H., Lieberman R., et al. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 22 (2004) 7583-7591
11. Bailey H.H., Levy D., Harris L.S., Schink J.C., Foss F., Beatty P., et al. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol 3 (2002) 464-468
12. Hardcastle I.R., Rowlands M.G., Barber A.M., Grimshaw R.M., Mohan M.K., Nutley B.P., et al. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 7 (1999) 801-809
13. Crowell P.L., Ren Z., Lin S., Vedejs E., and Gould M.N. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 8 (1994) 1405-1415
14. Mills J.J., Chari R.S., Boyer I.J., Gould M.N., and Jirtle R.L. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 5 (1995) 979-983
15. Fernandes J., da Fonseca C.O., Teixeira A., and Gattass C.R. Perillyl alcohol induces apoptosis in human glioblastoma multiforme cells. Oncol Rep 5 (2005) 943-947
16. Bardon S., Picard K., and Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutr Cancer 1 (1998) 1-7
17. Bardon S., Foussard V., Fournel S., and Loubat A. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 2 (2002) 187-194
18. Rajesh D., and Howard S.P. Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells. Prostate 1 (2003) 14-23
19. Carter P., Smith L., and Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 4 (2004) 659-687
20. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2 (2002) 114-130
21. Rabilloud T. Membrane proteins ride shotgun. Nat Biotechnol 5 (2003) 508-510
22. Hopkins A.L., and Groom C.R. The druggable genome. Nat Rev Drug Discov 9 (2002) 727-730
23. Josic D., and Clifton J.G. Mammalian plasma membrane proteomics. Proteomics 16 (2007) 3010-3029
24. Washburn M.P., Wolters D., and Yates III J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 3 (2001) 242-247
25. Liu H., Sadygov R.G., and Yates III J.R. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 14 (2004) 4193-4201
26. Carvalho P.C., Hewel J., Barbosa V.C., and Yates III J.R. Identifying differences in protein expression levels by spectral counting and feature selection. Genet Mol Res 2 (2008) 342-356
27. Carvalho P.C., Fischer J.S., Chen E.I., Yates III J.R., and Barbosa V.C. PatternLab for proteomics: a tool for differential shotgun proteomics. BMC Bioinformatics 9 (2008) 316
28. Carvalho P.C., Fischer J.S., Chen E.I., Domont G.B., Carvalho M.G., Degrave W.M., et al. GO Explorer: a gene-ontology tool to aid in the interpretation of shotgun proteomics data. Proteome Sci 7 (2009) 6
29. McDonald W.H., Tabb D.L., Sadygov R.G., MacCoss M.J., Venable J., Graumann J., et al. MS1, MS2, and SQT-three unified, compact, and easily parsed file formats for the storage of shotgun proteomic spectra and identifications. Rapid Commun Mass Spectrom 18 (2004) 2162-2168
30. Kersey P.J., Duarte J., Williams A., Karavidopoulou Y., Birney E., and Apweiler R. The International Protein Index: an integrated database for proteomics experiments. Proteomics 7 (2004) 1985-1988
31. Peng J., Elias J.E., Thoreen C.C., Licklider L.J., and Gygi S.P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res 1 (2003) 43-50
32. Tabb D.L., McDonald W.H., and Yates III J.R. DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J Proteome Res 1 (2002) 21-26
33. Eng J.K., McCormack L., Yates A., and Yates III J.R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5 (1994) 976-989
34. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57 (1995) 289-300
35. Corsi F., De P.C., Colombo M., Allevi R., Nebuloni M., Ronchi S., Rizzi G., Tosoni A., Trabucchi E., Clementi E., Prosperi D. Towards Ideal Magnetofluorescent Nanoparticles for Bimodal Detection of Breast-Cancer Cells. Small 2009.
36. Zhang B., VerBerkmoes N.C., Langston M.A., Uberbacher E., Hettich R.L., and Samatova N.F. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 11 (2006) 2909-2918
37. Barbacid M. Ras genes. Annu Rev Biochem 56 (1987) 779-827
38. Liu J.J., Chao J.R., Jiang M.C., Ng S.Y., Yen J.J., and Yang-Yen H.F. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 7 (1995) 3654-3663
39. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 11 (1999) 3631-3652
40. Chaudhary S.C., Alam M.S., Siddiqui M.S., and Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 2-3 (2009) 145-153
41. Abulrob A., Giuseppin S., Andrade M.F., McDermid A., Moreno M., and Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 41 (2004) 6967-6979
42. Martin S., Cosset E.C., Terrand J., Maglott A., Takeda K., and Dontenwill M. Caveolin-1 regulates glioblastoma aggressiveness through the control of alpha(5)beta(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an alpha(5)beta(1) integrin antagonist. Biochim Biophys Acta 2 (2009) 354-367
43. Jaattela M. Heat shock proteins as cellular lifeguards. Ann Med 4 (1999) 261-271
44. Nylandsted J., Brand K., and Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 926 (2000) 122-125
45. Hermisson M., Strik H., Rieger J., Dichgans J., Meyermann R., and Weller M. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 6 (2000) 1357-1365
46. Strik H.M., Weller M., Frank B., Hermisson M., Deininger M.H., Dichgans J., et al. Heat shock protein expression in human gliomas. Anticancer Res 6B (2000) 4457-4462
47. Gyrd-Hansen M., Nylandsted J., and Jaattela M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle 12 (2004) 1484-1485
48. Schaeffer H.J., and Weber M.J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 4 (1999) 2435-2444
49. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J 9 (1995) 726-735
50. Fischer J.S., Carvalho P.C., Gattass C.R., Paschoal E.M., da Mota e Silva M.S., and Carvalho M.G. Effects of perillyl alcohol and heat shock treatment in gene expression of human lung adenocarcinoma cell line A549. J Exp Ther Oncol 4 (2006) 301-307
51. Kim J.W., Lee J.E., Kim M.J., Cho E.G., Cho S.G., and Choi E.J. Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 16 (2003) 13995-14001
52. Takahashi-Yanaga F., Shiraishi F., Hirata M., Miwa Y., Morimoto S., and Sasaguri T. Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts. Biochem Biophys Res Commun 2 (2004) 411-415
53. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2 (2004) 95-102
54. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 4 (2001) 391-426
55. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urrutia R.A., and Billadeau D.D. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 6 (2005) 2076-2081
56. Demarchi F., Bertoli C., Sandy P., and Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem 41 (2003) 39583-39590
57. Tan J., Zhuang L., Leong H.S., Iyer N.G., Liu E.T., and Yu Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 19 (2005) 9012-9020
58. Kotliarova S., Pastorino S., Kovell L.C., Kotliarov Y., Song H., Zhang W., et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 16 (2008) 6643-6651
59. Wang Q., Zhou Y., Wang X., and Evers B.M. Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. Oncogene 1 (2006) 43-50
60. Persad S., Troussard A.A., McPhee T.R., Mulholland D.J., and Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 6 (2001) 1161-1174
61. Aberle H., Bauer A., Stappert J., Kispert A., and Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 13 (1997) 3797-3804
62. Polakis P. Casein kinase 1: a Wnt'er of disconnect. Curr Biol 14 (2002) R499-R501
63. Cadigan K.M., and Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 24 (1997) 3286-3305